Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Total Current Liabilities: 2019-2025

Historic Total Current Liabilities for Legend Biotech (LEGN) over the last 5 years, with Sep 2025 value amounting to $433.6 million.

  • Legend Biotech's Total Current Liabilities rose 60.05% to $433.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $433.6 million, marking a year-over-year increase of 60.05%. This contributed to the annual value of $277.6 million for FY2024, which is 28.29% up from last year.
  • Legend Biotech's Total Current Liabilities amounted to $433.6 million in Q3 2025, which was up 63.32% from $265.5 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Total Current Liabilities registered a high of $433.6 million during Q3 2025, and its lowest value of $145,942 during Q1 2021.
  • For the 3-year period, Legend Biotech's Total Current Liabilities averaged around $259.7 million, with its median value being $249.7 million (2024).
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 226,883.16% in 2021, then dropped by 27.32% in 2023.
  • Quarterly analysis of 5 years shows Legend Biotech's Total Current Liabilities stood at $229.2 million in 2021, then increased by 29.92% to $297.8 million in 2022, then fell by 27.32% to $216.4 million in 2023, then increased by 28.29% to $277.6 million in 2024, then soared by 60.05% to $433.6 million in 2025.
  • Its last three reported values are $433.6 million in Q3 2025, $265.5 million for Q2 2025, and $234.4 million during Q1 2025.